A. Vogel AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Private
- Established
- 1963-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.avogel-company.ch
Clinical Trials
15
Active:0
Completed:10
Trial Phases
4 Phases
Phase 2:1
Phase 3:4
Phase 4:7
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Phase 4
7 (50.0%)Phase 3
4 (28.6%)Not Applicable
2 (14.3%)Phase 2
1 (7.1%)Eschscholzia Study
Phase 3
Not yet recruiting
- Conditions
- Sleep
- Interventions
- Drug: Eschscholzia tabletsDrug: Placebo Tablets
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 100
- Registration Number
- NCT06795776
- Locations
- 🇧🇬
Diagnostics and Consultation Center Convex, Sofia, Bulgaria
Mental Balance Study
Not Applicable
Completed
- Conditions
- Work Related StressMental Health Wellness 1
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 36
- Registration Number
- NCT05757050
- Locations
- 🇬🇧
Northumbria University, Newcastle Upon Tyne, Tyne & Wear, United Kingdom
Sleep Well Observation Study
Not Applicable
Completed
- Conditions
- Sleep Disturbance
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 50
- Registration Number
- NCT05748574
- Locations
- 🇩🇪
daacro GmbH & Co. KG, Trier, Rheinland-Pfalz, Germany
Echinaforce Study to Investigate Explorative Pharmacology and Effectiveness to Prevent From Enveloped Virus Infections
Phase 4
Completed
- Conditions
- Respiratory Tract InfectionsCommon Cold
- Interventions
- Drug: Echinaforce Chewable tablets
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 122
- Registration Number
- NCT05002179
- Locations
- 🇧🇬
Diagnostics and Consultation Center Convex EOOD, Sofia, Bulgaria
Echinaforce COVID-19 Shedding Study
Phase 4
Terminated
- Conditions
- COVID-19 Respiratory InfectionSARS-CoV2 Infection
- Interventions
- Drug: Echinaforce Forte tabletsDrug: Echinaforce Chewable tabletsDrug: Echinaforce tincture
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- A. Vogel AG
- Target Recruit Count
- 40
- Registration Number
- NCT04999098
- Locations
- 🇧🇬
Diagnostics and Consultation Center Convex EOOD, Sofia, Bulgaria
- Prev
- 1
- 2
- 3
- Next
News
No news found